PDGFRB and sarcoma: In fact, the blockage of PDGFR-β expression with imatinib, a TKI used in human medicine, decreases the epithelial-mesenchymal transition (EMT) and the transcription of factor Slug, and it dramatically reduces the progression of human sarcomas [44].